> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# AlgoTx Will Continue ATX01 15% Development
- URL: https://www.fdaweb.com/algotx-will-continue-atx01-15-development/
- Published: 2025-02-18T12:00:00.000Z
- Updated: 2026-09-14T14:53:20.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5158678

AlgoTx says that based on mixed results from the Phase 2 ACT trial, it sees a path to continue to develop ATX01, its first-in-class therapeutic for chemotherapy-induced peripheral neuropathic pain. A company [announcement](https://algotx.com/2025/02/18/algotx-announces-results-of-its-phase-2-act-trial-of-atx01-in-chemotherapy-induced-peripheral-neuropathy/?ref=fdaweb.com) said the trial “provided encouraging signs of ATX01 efficacy, particularly at the higher concentration of 15%. However, the high level of placebo effect experienced in several study sites prevented the overall separation of the pain response curves for ATX01 and placebo.” Company officials say they will use the results to help design a new study.

“While we have seen encouraging signs of clinical efficacy with ATX01, we did not hit our primary endpoint due to a strong placebo effect in some centers,” said AlgoTx CEO **Stéphane Thiroloix**. “Hence there is the potential to design a new study, with additional mitigation strategies in place, to evaluate ATX01’s efficacy to alleviate pain … without ambiguity. There remains a very high unmet need for pain relief in approximately two-thirds of patients treated for cancer.”